Detalhe da pesquisa
1.
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Cancer Immunol Immunother
; 70(6): 1583-1592, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33231726
2.
Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC.
Curr Probl Cancer
; 46(1): 100787, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34489119
3.
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
Clin Lung Cancer
; 22(4): 351-360, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33558194
4.
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Cancers (Basel)
; 12(5)2020 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32397295